Joseph R. Osborne, M.D., Ph.D.
Tel: 212-746-6797 Email: jro7001@med.cornell.edu

EDUCATION:

COLUMBIA UNIVERSITY, New York, N.Y. 1992 - 2001
Ph.D., Integrated Program in Cellular and Molecular Biophysics
Advisor: Richard Axel – Higgins Professor of Biochemistry and Biophysics
2004 Nobel Laureate in Physiology or Medicine

M.D., College of Physicians & Surgeons
Columbia Presbyterian Medical Center

BROWN UNIVERSITY, Providence, R.I. 1988 - 1992
B.S., Neuroscience

POSTDOCTORAL AND GRADUATE MEDICAL TRAINING:

CPMC NUCLEAR MEDICINE SECTION 2007 - 2008
Phillip Johnson Nuclear Radiology Fellow

COLUMBIA PRESBYTERIAN HOSPITAL (CPMC), New York, N.Y. 2003 - 2007
DEPARTMENT OF RADIOLOGY **–** Chief Resident 2006 - 2007

MEMORIAL SLOAN KETTERING CANCER CENTER 2002 - 2003
DEPARTMENT OF NUCLEAR MEDICINE, New York, N.Y. 2003 - 2007
Post-doctoral fellowship – In vivo Cellular and Molecular Imaging
Advisor: Dr. Steven Larson – Chief, Nuclear Medicine Service

WASHINGTON HOSPITAL CENTER, Washington D.C. 2001 - 2002
INTERNAL MEDICINE DEPARTMENT- Internship

PROFESSIONAL POSITIONS AND EMPLOYMENT:

WEILL CORNELL MEDICAL COLLEGE 2018 - present
RADIOLOGY DEPARTMENT, New York, N.Y.
Chief, Molecular Imaging & Therapeutics Service
Associate Attending of Radiology

MEMORIAL SLOAN KETTERING CANCER CENTER 2012 - 2018
RADIOLOGY DEPARTMENT, New York, N.Y.
Associate Member – Molecular Imaging and Therapy Service
Associate Vice Chairman of Research – Radiology
Former Director – Molecular Imaging and Therapy Residency/Fellowship Programs

WEILL CORNELL MEDICAL COLLEGE 2008 - 2012
RADIOLOGY DEPARTMENT, New York, N.Y.
Assistant Attending of Radiology - Division of Nuclear Medicine
Director – Nuclear Medicine / Molecular Imaging Residency Program

LICENSURE, BOARD CERTIFICATION:

LICENSURE:
New York State No. 230706
Date of issue 12/5/03. Current registration 12/16 – 12/18
DEA number: FOO186610
NPI number: 1710006283

CERTIFICATION:
American Board of Radiology No. 53602, Renewed, reissue 01/18
American Board of Nuclear Medicine No. 7875, Expires 11/20

PROFESSIONAL MEMBERSHIPS:

New York Roentgen Society	No. 05024380
American College of Radiology	No. 05024380
Society of Nuclear Medicine	No. 275369
American Association of Cancer Research	No. 244263

LABORATORY AND INTRAMURAL PROFESSIONAL RESPONSIBILITIES:

WCM
Clinical Chief of the Molecular Imaging Innovation Institute (MI3)
Director - Molecular Imaging Innovations Institute lab for inclusion (MI4)
MI4 - We have a dual interest in molecular imaging probe development and the genetic/socioeconomic causes of the uneven burden of illness. As it is now known that specific genomic mutations can be exploited for more effective diagnosis and treatment, we will further explore how this is reflected in various subpopulations. We believe that this novel approach will have a significant impact on our patient. From the diagnostic perspective, we will continue to have a strong focus on the next generation of molecular imaging probes, but will focus on finding means of cost-effective and practical integration. It is our belief that cost effective diagnostics will translate to broader access to more effective therapeutics.

MSKCC
Associate Vice Chair of Research - Radiology
Associate Vice-Chair (AVC) for Research in Radiology acting as the physician liaison to the Deputy Physician-in-Chief of the organization,

INTRAMURAL ADMINISTRATIVE RESPONSIBILITIES:

Weill Cornell Medical College: Administrative/Institutional Committees

Radioactive Drug Research Committee	Pending
Cyclotron Steering Committee, WCMC and MSKCC	Pending
Program Director, Molecular Imaging Residency Program	2011 - 2012
RADI05B: Introduction to Nuclear Medicine Medical Student Elective	2011 – 2013
Data Safety and Monitoring Board	2010 - 2013
Formulary and Therapeutics Committee	2011 – 2012

MSKCC: Administrative/Institutional Committees

Molecular Imaging and Therapy Service - Mini-Fellowship Director	2012 - 2018
Molecular Imaging and Therapy Service - Medical School Elective Director	2013 - 2018
Molecular Imaging and Therapy Service - Observership Director	2014 - 2018
Molecular Imaging and Therapy Service - Training Program Director	2013 - 2016

Investigational New Drug (IND) Committee – MSKCC 2015 - 2018

Columbia University: Administrative

ABPM 4701: Anatomy for the Engineer or Physicist, 2009 - 2010
Columbia University Applied Math & Applied Engineering

EXTRAMURAL RESPONSIBILITIES:

NIH IPCA - Imaging Probes and Contrast agents Study Section 11**/**2018- 06/2019
The Imaging Probes and Contrast Agents [IPCA] study section reviews proposals to develop novel contrast agents of all sorts. Studies typically involve the evaluation of new agents with an emphasis on steps such as synthesis, identification of lead candidates, tracer characterization, safety, dosing, and validation preclinically and clinically.

NIH MEDI - Medical Imaging Study Section – Chartered Member 02/2011 - 11/2018
The Medical Imaging [MEDI] Scientific Review Group reviews proposals involving the application and validation of in vivo imaging of humans and animals, including early phase clinical studies of medical imaging systems, molecular probes and contrast agents, software, molecular imaging techniques, and related technologies. The underlying technologies may be refined and optimized during testing in response to research questions or clinical needs.

NIH Special Emphasis Panels 09/2017 – 5/2018
Chair "Early Phase Clinical Trials in Imaging & Image Guided Interventions"
Chair "Imaging & Biomarkers for Early Detection of Aggressive Cancer"
Member "Bioengineering Research Partnership"

ACR Nuclear Medicine Guidelines Committee 10/2013 – 10/2015
Chair, ACR Appropriateness criteria for unsealed therapeutic radiopharmaceutical sources

SNMMI–FDA Task Force 10/2014 – 06/2019
The task force was created to create a more efficient and timely approval process for new and non-proprietary radiotracers and radio-therapeutics by the U.S. Food and Drug Administration (FDA).

1) To optimize evidentiary requirements for the approval of new radiotracers.
2) To optimize evidentiary requirements for the approval of radio-therapeutics.
3) To engage FDA in dialogue on SNMMI's recommendations of possible pathways to improving the review and approval process.
4) To improve clinical access and reimbursement for non-approved radiolabeled agents under development (traditional IND) or under an Expanded Access IND

Damon Runyon-Rachleff Research Foundation
Innovator Award Committee Reviewer 10/2016 - present
The Innovation Award is an early career, "high-risk/high-reward" mechanism designed to support creative thinking in the best of next generation's scientists. The accepted proposals are cultivated to impact the thought process of all investigating the prevention, diagnosis and/or treatment of cancer.

NYC Metro committee 10/2017 - present
Committee members participate in the formulation of fundraising and awareness strategies for the region and Identify potential new donors and participate in cultivation and solicitation activities

INTRAMURAL RESEARCH

CLINICAL TRIALS (PI, transferring or closing currently)

1. Protocol #17-115 (in development) "Bioequivalence Study of Two ^{68}Ga Small Molecule PSMA

Antagonists" Complement protocol to R01
2. Protocol #16-306 "PSMA PET imaging of recurrent prostate cancer" (^{68}Ga-PSMA cost recovery)
3. Protocol #16-696 "Imaging Pathology Correlation in Thyroid Cancer."
4. Protocol X15-032 "Introducing a Cultural and Linguistic Responsiveness Training Intervention to the Molecular Imaging and Therapy Service."
5. Protocol X17-004 "Administrative Supplements for NCI-designated Cancer Centers to Support Population Health Assessment in Cancer Center Catchment Areas."

Physician Sponsored IND
IND #115521 ^{89}Zr-J591 for localized prostate cancer. 2012 - 2014

CURRENT RESEARCH SUPPORT:

R01 CA207645-01, NIH/NCI 07/16 - 06/19
A New Technique to Make ^{68}Ga-labeled Pharmaceuticals Widely Available for Clinical Use.
PI: Osborne
Role: PI

R01 CA201250- 01A1 NIH/NCI 08/16 - 07/21
^{124}I NaI PET: Building block for precision medicine in metastatic thyroid cancer.
PI: Larson/Humm/Tuttle
Role: Co-Investigator

DoR-CBIC Research Pilot Award 01/19 – 01/20
Gallium 68 Citrate Imaging in Orthopedic Infections"
Role: Principal Investigator

PCF Challenge Award 09/17 – 08/19
"Optimization of prostate-specific membrane antigen-targeted radiation."
Tagawa (PI)
Role: Co-I

Meyer Cancer Center (MCC) Catchment Award 12/18 - 11/19
"Population health assessment survey of four target neighborhoods in the MCC catchment"
Phillips (PI)
Role: Co-I

Dean's Health Disparity Research Award 04/19 – 04/20
"WCM catchment Prostate Cancer Health Impact Program (pCHIP)"
Role: Principle Investigator

1R01HL144541-01A1 08/19 – 07/24
"MRI Detection of CarotId Plaques as a mecHanism for Embolic strokes of undeteRmined source (MRI DECIPHER)"
Gupta (PI)
Role: Co-I

COMPLETED RESEARCH SUPPORT:

Osborne Innovation Fund – Office of the MSK COO 08/2016 - present
Introducing a Cultural and Linguistic Responsiveness Training Intervention to the Molecular Imaging and Therapy Service (MITS).

Role: PI

P30 CA008748-50 S4 NIH/NCI 09/2016 - 06/2018
Bedford-Stuyvesant & Bushwick: Cancer Health Impact Program (CHIP).
Role: PI/Project Leader

P30 CA008748, MSKCC SOAR Network 09/2014-08/2015
Aging-Related Genes, Cognitive Functions, and Amyloid Imaging in Brain Tumor Patients.
PI: Correa,
Role: Co-PI

1 R21 CA153177-01, NIH/NCI 09/2011 - 09/2013
Immuno-PET with Anti-PSMA ^{89}Zr-J591 mAb For Molecular Imaging of Prostate Cancer
Role: PI

PEER REVIEWED PUBLICATIONS:

1. Gogos JA, **Osborne J,** Nemes A, Mendelsohn M, Axel R. Genetic ablation and restoration of the olfactory topographic map. Cell. 2000; 03(4):609-20.

2. Eggan K, Baldwin K, Tackett M, **Osborne J,** Gogos J, Chess A, Axel R, Jaenisch R. Mice cloned from olfactory sensory neurons. Nature. 2004; 428 (6978):44-9.

3. Yu CR, Power J, Barnea G, O'Donnell S, Brown HE, **Osborne J,** Axel R, Gogos JA. Spontaneous neural activity is required for the establishment and maintenance of the olfactory sensory map. Neuron. 2004; 42(4):553-66.

4. Gade TP, Hassen W, Santos E, Gunset G, Saudemont A, Gong MC, Brentjens R, Zhong XS, Stephan M, Stefanski J, Lyddane C, **Osborne JR,** Buchanan IM, Hall S1, Heston WD, Riviere I, Larson SM, Koutcher A, Sadelain M. Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Res. 2005; 65(19):9080-8.

5. Tagawa ST, Beltran H, Vallabhajosula S, Goldsmith S1, **Osborne J,** Matulich D, Petrillo K, Parmar S, Nanus OM, Bander NH. Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer. 2010;116(4 Suppl):l075-83.

6. Shih G, Lu ZF, Zabih R, Kennedy D, Loftus M, Shih W1, **Osborne J**, Nickoloff E, Schwartz L. Automated framework for digital radiation dose index reporting from CT dose reports. AJR Am J Roentgenol 2011;197(5):1170-4

7. Palaskas N, Larson SM, Schultz N, Komisopoulou E, Wong J, Rohle D, Campos C, Yannuzzi N, **Osborne JR,** Linkov I, Kastenhuber ER, Taschereau R, Plaisier SB, Tran C, Heguy A; Wu H, Sander C, Phelps ME, Brennan C, PortE, Huse JT, Graeber TG, Mellinghoff IK. l8F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers. Cancer Res. 2011; 71(15):5164-74.

8. Wilson SR. Leonard JP, Geyer JT, **Osborne JR**, Weinsaft JW. A worrisome interventricular septum: more than meets the eye. J Am Coll Cardiol. 2011; 58(24):e43.

9. Butler T, Ichise M, Teich AF, Gerard E, **Osborne J,** French J, Devinsky O, Kuzniecky R, Gilliam F, Pervez F, Provenzano F, Goldsmith S, Vallabhajosula S, Stem E, Silbersweig D. Imaging

Inflammation in a Patient with Epilepsy Due to Focal Cortical Dysplasia. J Neuroimaging. 2013; 23(1):129-31

10. **Osborne JR**, Spratt DE, Green DA, Fareedy SB, Robinson BD, Beattie BJ, Jain M, Lewis J, Christos P, Larson SM, Bander NH, Scherr DS. A Pilot Study of 89Zr-J591/PSMA Positron Emission Tomography (PET) in Men with Localized Prostate Cancer Undergoing Radical Prostatectomy. J Urol. 2014;1(5):1439-45.

11. Vallabhajosula S, Nikolopoulou A, Babich JW, **Osborne JR**, Tagawa ST, Lipai I, Solnes L, Maresca KP, Armor T, Joyal JL, Crummet R, Stubbs JB, Goldsmith SJ. ^{99m}Tc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen: Pharmacokinetics and Biodistribution Studies in Healthy Subjects and Patients with Metastatic Prostate. J Nucl Med. 2014; Nov, 55(11):1791-8

12. Pandit-Taskar N, O'Donoghue JA, Beylergil V, Lyashchenko S, Ruan S, Solomon SB, Durack JC, Carrasquillo JA, Lefkowitz RA, Gonen M, Lewis JS, Holland JP, Cheal SM, Reuter VE, **Osborne JR**, Loda MF, Smith-Jones PM, Weber WA, Bander NH, Scher HI, Morris MJ, Larson SM. $^{(89)}$Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2014; Nov, 41(11):2093-105

13. Elstrom RL, Ruan J, Christos PJ, Martin P, Lebovic D, **Osborne J**, Goldsmith S, Greenberg J, Furman RR, Avram A, Putman R, Chapman E, Mazumdar M, Griffith K, Coleman M, Leonard JP, Kaminski MS. Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with (131)I-tositumomab. Leuk Lymphoma. 2015; 56(2):342-6

14. Pandit-Taskar N, O'Donoghue JA, Durack JC, Lyashchenko SK, Cheal SM, Beylergil V, Lefkowitz RA, Carrasquillo JA, Martinez DF, Fung AM, Solomon SB, Gonen M, Heller G, Loda M, Nanus DM, Tagawa ST, Feldman JL, **Osborne JR**, Lewis JS, Reuter V, Weber WA, Bander NH, Scher HI, Larson SM, Morris MJ. A Phase I/II Study for Analytic Validation of 89Zr-J591 Immuno PET as a Molecular Imaging Agent for Metastatic Prostate Cancer. Clin Cancer Res. 2015; 21(23):5277-85

15. Sofocleous CT, Violari EG, Sotirchos VS, Shady W, Gonen M, Pandit-Taskar N, Petre EN, Brody LA, Alago W, Do RK, D'Angelica MI, **Osborne JR**, Segal NH, Carrasquillo JA, Kemeny NE. Radioembolization as a Salvage Therapy for Heavily Pretreated Patients With Colorectal Cancer Liver Metastases: Factors That Affect Outcomes. Clin Colorectal Cancer. 2015; Dec. 14, (4):296-305

16. Parsons M, Goldman D, Dashevsky B, Riedl CC, Gonen M, **Osborne J,** Jochelson M, Hudis C, Morrow M, Ulaner G. Value of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Breast Cancer (ILC) as Compared with Invasive Ductal Breast Cancer (IDC). J Nucl Med. 2015; 56(11):1674-80

17. Spratt DE and **Osborne JR**. Disparities in Castrate-Resistant Prostate Cancer Clinical Trials. J Clin Oncol. 2015 Apr 1;33(10):1101-3

18. **Osborne JR.** Guest Editorial. Semin Nucl Med. 2016 Jan;46(1):3-4

19. Arevalo-Perez J, Paris M, Graham MM, **Osborne JR**. A Perspective of the Future of Nuclear Medicine Training and Certification. Semin Nucl Med. 2016 Jan;46(1):88-96

20. **Osborne JR**, Beylergil V, Samitt C, Graham MM. Roundtable on the Future of Nuclear Medicine Training. J Nucl Med. 2015 Dec;56(12):PMID: 26429952.

21. Spratt DE, Perez JA, Leeman JE, Gerber NK, Folkert M, Taunk NK, Alektiar KM, Karimi S, Lyo JK, Tap WD, Bilsky MH, Laufer I, Yamada Y, **Osborne JR**. Early magnetic resonance imaging biomarkers to predict local control after high dose stereotactic body radiotherapy for patients with sarcoma spine metastases. Spine J. 2016; 16 (3): 291-8

22. Fung EK, Cheal SM, Fareedy SB, Punzalan B, Beylergil V, Amir J, Chalasani S, Weber WA, Spratt DE, Veach DR, Bander NH, Larson SM, Zanzonico PB, **Osborne JR.** Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling. EJNMMI research. 2016; 6(1):7.

24. Spratt Das DK, Naidoo M, Ilboudo A, Park JY, Ali T, Krampis K, Robinson BD, **Osborne JR**, Ogunwobi OO. miR-1207-3p regulates the androgen receptor in prostate cancer via FNDC1/fibronectin. Experimental cell research. 2016; 348(2):190-200.

25. Spratt, DE, **Osborne JR**, Zumsteg ZS, Rebeiz K, Leeman J, Rivera A, Morris MJ, Zelefsky MJ. Radium-223 outcomes after multiple lines of metastatic castration-resistant prostate cancer therapy in clinical practice: implication of pre-treatment spinal epidural disease. Prostate Cancer Prostatic Dis. 2016; 19(3):271-6.

26. Spratt DE, Chan T, Waldron L, Speers C, Feng FY, Ogunwobi OO, Osborne JR. Racial/ Ethnic Disparities in Genomic Sequencing. JAMA Oncol. 2016; 2(8): 1070-4

27. Leeman JE, Bilsky M, Laufer I, Folkert MR, Taunk NK, **Osborne JR**, Arevalo-Perez J, Zatcky J, Alektiar KM, Yamada Y, Spratt DE. Stereotactic body radiotherapy for metastatic spinal sarcoma: a detailed patterns-of-failure study. J Neurosurg Spine. 2016 Jul; 25(1):52-8.

28. Das DK, **Osborne JR**, Lin HY, Park JY, Ogunwobi OO. miR-1207-3p Is a Novel Prognostic Biomarker of Prostate Cancer. Transl Oncol. 2016 ;9(3):236-41

29. Shady W, Kishore S, Gavane S, Do RK, **Osborne JR**, Ulaner GA, Gonen M, Ziv E, Boas FE, Sofocleous CT. Metabolic tumor volume and total lesion glycolysis on FDG-PET/CT can predict overall survival after (90)Y radioembolization of colorectal liver metastases: A comparison with SUVmax, SUVpeak, and RECIST 1.0. Eur J Radiol 2016; 85(6):1224-31

30. Spratt DE, Beadle BM, Zumsteg ZS, Rivera A, Skinner HD, **Osborne JR**, Garden AS, Lee NY. The Influence of Diabetes Mellitus and Metformin on Distant Metastases in Oropharyngeal Cancer: A Multicenter Study. Int J Radiat Oncol Biol Phys. 2016 1; 94(3):523-31

31. Spratt D, Zaki BI, Franc BL, Hartford AC, **Osborne JR.** ACR Practice Parameter for the Performance of Therapy with Unsealed Radiopharmaceutical Sources. Clin Nucl Med. 2016; 41 (2):106-17.

32. Spratt DE, Chen YW Mahal BA, **Osborne JR**, Zhao SG, Morgan TM, Palapattu G, Feng FY, Nguyen PL. Individual Patient Data Analysis of Randomized Clinical Trials: Impact of Black Race on Castration-resistant Prostate Cancer Outcomes. European Urology Focus, In Press, online 1 2016

33. Das DK, Naidoo M, Ilboudo A, Park JY, Ali T, Krampis K, Robinson BD, **Osborne JR**, Ogunwobi OO. miR-1207-3p regulates the androgen receptor in prostate cancer via FNDC1/fibronectin. Exp Cell Res. 2016 Nov 1;348(2):190-200

35. Soliman M, Taunk, NK, Simons, R.E., **Osborne, JR**, Kim, MM, Szerlip, NJ, Spratt, DE. Anatomic and functional imaging in the diagnosis of spine metastases and response assessment after spine radiosurgery Neurosurgical Focus *Jan 2017* / Vol. 42 / No. 1, Page E5

37. Wahl DR, Nguyen PL, Santiago M, Yousefi K, Davicioni E, Shumway DA, Speers C, Mehra R, Feng FY, **Osborne JR**, Spratt DE. Pan-Cancer Analysis of Genomic Sequencing in the Elderly. Int J Radiat Oncol Biol Phys. 2017 Jan 7 [Epub ahead of print]

38. Spratt DE, Vargas HA, Zumsteg ZS, Golia Pernicka JS, **Osborne JR,** Pei X, Zelefsky MJ. Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage. Eur Urol. 2017 Jan;71(1):37-43

39. Larson SM, **Osborne JR**, Grewal RK, Tuttle RM. Redifferentiating Thyroid Cancer: Selumetinib-enhanced Radioiodine Uptake in Thyroid Cancer. Mol Imaging Radionucl Ther. 2017 Feb 9;26(Suppl 1):80-86

40. Wahl DR, Nguyen PL, Santiago M, Yousefi K, Davicioni E, Shumway DA, Speers C, Mehra R, Feng FY, **Osborne JR**, Spratt DE. Pan-Cancer Analysis of Genomic Sequencing Among the Elderly. Int J Radiat Oncol Biol Phys. 2017 Jul 15;98(4):726-732

41. Huang FW, Mosquera JM, Garofalo A, Oh C, Baco M, Amin-Mansour A, Rabasha B, Bahl S, Mullane SA, Robinson BD, Aldubayan S, Khani F, Karir B, Kim E, Chimene-Weiss J, Hofree M, Romanel A, **Osborne JR**, Kim JW, Azabdaftari G, Woloszynska-Read A, Sfanos K, De Marzo AM, Demichelis F, Gabriel S, Van Allen EM, Mesirov J, Tamayo P, Rubin MA, Powell IJ, Garraway LA. Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations. Cancer Discov. 2017 Sep;7(9):973-983

42. Fox JJ, Gavane SC, Blanc-Autran E, Nehmeh S, Gönen M, Beattie B, Vargas HA, Schöder H, Humm JL, Fine SW, Lewis JS, Solomon SB, **Osborne JR**, Veach D, Sawyers CL, Weber WA, Scher HI, Morris MJ, Larson SM. Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer. JAMA Oncol. 2017 Nov 9

43. Correa DD, Kryza-Lacombe M, Zhou X, Baser RE, Beattie BJ, Beiene Z, Humm J, DeAngelis LM, Orlow I, Weber W, **Osborne J**. A pilot study of neuropsychological functions, APOE and amyloid imaging in patients with gliomas. J Neurooncol. 2017 Nov 22

44. **Osborne JR**, Kalidindi TM, Punzalan BJ, Gangangari K, Spratt DE, Weber WA, Larson SM, Pillarsetty NVK. Repeatability of [68Ga] DKFZ11-PSMA PET Scans for Detecting Prostate-specific Membrane Antigen-positive Prostate Cancer. Mol Imaging Biol. 2017 Dec;19(6):944-951

45. Ramirez-Fort MK, Mahase SS, **Osborne JR**, Lange CS. Theragnostic Target, Prostate-Specific Membrane Antigen-Also Specific for Nonprostatic Malignancies. Int J Radiat Oncol Biol Phys. 2018 Jul 1;101(3):646-649. doi: 10.1016/j.ijrobp.2018.03.061. Epub 2018 Apr 5. No abstract available. PMID: 29893276

46. Costas-Muniz R, Amir J, Paris M, Spratt D, Arevalo-Perez J, Fareedy S, González CJ, Gany F, Camacho-Rivera M, **Osborne JR**. Interventional Cultural and Language Assistance Program: Associations between Cultural and Linguistic Factors and Satisfaction with Cancer Care. J Community Med Health Educ. 2017;7(1). pii: 503. doi: 10.41